

PERSONAL INFORMATION

BALASA RODICA



WORK EXPERIENCE

2017 – PRESENT

Director of Doctoral School - (I.O.S.U.D)

University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania

2017 – PRESENT

University Professor Habil (MENCS order, no. 3708/13.04.2017)

University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania

2015 - PRESENT

University Professor

Neurology Department, University of Medicine, Pharmacy, Science and Technology „George Emil Palade” of Targu Mures (UMFST), Romania

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania
Complex didactic activity - classes, internships and practical sessions with students from the Romanian and English sections, 5th year general medicine, 3rd year balneo and kinetotherapy (BKT), 1st year BKT bachelor studies, coordinator for the junior neurologists (years 1-5) and research (grant director, principal investigator in multicentric studies.

2006 - PRESENT

Head of Neurology 1 Clinic (decision no.236/ 2006)

Neurology 1 Clinic, Emergency Clinical County Hospital Targu Mures.

- Gheorghe Marinescu Str, No. 50, 540136, Targu Mures (Romania)

2003 - PRESENT

Organizational and medical activities of a neurology clinic with 70 beds and over 70 subordinates.

Senior neurologist (Order of MS 846/12.09.2003, no. VIII/d/MB/3107 from 15.09.2003)

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

- Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2005 - PRESENT

Neurology headmaster (appointed by the meeting of the UMF Senate Bureau Targu Mures, no. 8277 / 24 oct. 2005)

University of Medicine and Pharmacy of Targu Mures, Neurology, Department M4

- Gheorghe Marinescu Str., no. 38, 540142, Targu Mures, Romania
Guidance and coordination of the university and post-university education.

2017 – PRESENT**Coordinator of the national programme for neurological disorders – Multiple Sclerosis**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2017 – PRESENT**Coordinator of the national programme for rare neurological disorders – treatment of patients with acute degenerative and inflammatory-immune pathologies**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2017 - PRESENT**Coordinator of the national programme for rare neurological disorders – treatment of patients with chronic degenerative and inflammatory – immune pathologies**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2012 – PRESENT**Coordinator of the national programme of fibrinolysis therapy for ischemic stroke (AP-AVC)**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2009 – PRESENT**Coordinator of the national programme of diagnosis and treatment for rare diseases and severe sepsis – Myasthenia Gravis**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

2005 – PRESENT**Coordinator of the regional center for multiple sclerosis treatment**

Emergency Clinical County Hospital Targu Mures, Neurology 1 Clinic

▪ Gheorghe Marinescu Str, No. 50, 540136, Targu Mures, Romania

EDUCATION AND TRAINING

- 1984-1988** **Graduate of the Unirea Theoretical Lyceum, Targu Mures, Baccalaureate Diploma, F Series, no. 39184, average grade 9.71**
- 1988-1994** **General medicine/Doctor, Student/Licence diploma (series and no. M 000515/1994), Head of the promotion, average grade 10 (transcript no. 6633)**
UMF Targu Mures
- 1994-1999** **Intern doctor/position 41 out of 1087 (MS address no.VIII/B/22540/1994)**
National residency contest 1994, University of Medicine and Pharmacy Carol Davila, Bucharest
- 1996-2003** **Doctor in medical sciences PHD (C series, no. 0008787, MEC order no. 4741/25.08.2003), CUM LAUDE in Medicine, Neurology**
UMF Targu Mures
- 2000-2003** **Junior neurologist /average grade 10 (MS address no. VIII/B/GH/8627/10.12.1999)**
Specialist/junior neurologist competition 2000, University of Medicine and Pharmacy Iuliu Hațeganu, Cluj-Napoca
- 2006-2006** **Master (MEC diploma, F series, no. 0017884), Security, Health and Work Relations Management**
Lucian Blaga University, Sibiu
- 2003-PRESENT** **Primary Physician, average grade 9.77 (MS address no. VIII/d/MB/3107/15.09.2003)**
Primary Physician contest, 2003, University of Medicine and Pharmacy Carol Davila, Bucharest
- 1995-1998** **Associate Instructor (UMF Targu Mures, no.102 / 16.03.1995)**
UMF Targu Mures, Neurology, M4 Department
- 1999-2003** **Assistant professor (UMF Targu Mures, no. 4630 /1999)**
UMF Targu Mures, Neurology, M4 Department
- 2004-2007** **Lecturer (MEC order no. 9594 / 11.04.2004, UMF Senate decision, Targu Mures no. 86/ 2004)**
UMF Targu Mures, Neurology, M4 Department
- 2007-2015** **Associate Professor (decision no.300/13.09.2007)**
UMF Targu Mures, Neurology, M4 Department

PERSONAL SKILLS

Mother tongue Romanian

Foreign Languages

	UNDERSTANDING		SPEAKING		WRITING
	LISTENING	READING	SPOKEN INTERACTION	SPOKEN PRODUCTION	
ENGLISH	C1	C1	C1	C1	B2
FRENCH	C2	C2	C2	C2	B2

Organisational / managerial skills

Head of clinic - Neurology 1 Clinic of the Emergency Clinical County Hospital, Targu Mures, Headmaster of the Neurology Department, UMFST Targu Mures, Faculty of Medicine in English Director of the doctoral school (I.O.S.U.D.) Head of the Committee responsible for learning quality in the UMF Targu Mures Senate. Responsible for a team of 7 researchers Responsible for Good Clinical Practice guidelines in the Neurology 1 Clinic of the Emergency Clinical County Hospital, Targu Mures,

ADDITIONAL INFORMATION

A. RESEARCH GRANTS

I.1. National Research Grants – project manager

I.1.1 The role of cytokines in the immunopathogenesis of multiple sclerosis/autoimmune experimental encephalomyelitis and the evaluation of the immunomodulatory therapy using biomarkers, COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS, 2014, UMF Targu Mures, Contract No: 18/2015, amount 90000 RON, duration 2014-2016.

I.1.2 The role of cytokines in the heterogenous response of patients with multiple sclerosis to the immunomodulatory therapy, C COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS FINANCED EXCLUSIVELY BY PRIVATE FUNDS, session 2014, UMF Targu Mures, Contract No: 16171/2014, amount 23000 RON, duration 2014-2015.

I.1.3 Regional controlled hypothermia in therapeutical purposes, CNCSIS code 1346/2006, amount 65000 RON, duration 2006-2008.

I.2 National Research Grants – team member:

I.2.1 The study of chemokine CXCL 13, early diagnostic marker in Lyme neuroborreliosis versus other infections of the nervous system, COMPETITION FOR COLLECTIVE SCIENTIFIC RESEARCH GRANTS FINANCED EXCLUSIVELY BY PRIVATE FUNDS, 2014, UMF Targu Mures, Contract No: 13894/2014, amount: 25000 RON, duration: 2014-2015.

I.2.2 Grant CNCSIS Capacitati modul I No. 191 (CP/I/2007): A pilot centre to monitor the pharmacotherapy after pharmacokinetic criteria within the Drug Testing Laboratory Univ.Med.Pharm. Targu Mures (amount 933000 RON, duration: 2007-2009).

I.2.3 Technical expert in the Advanced centre of medical and pharmaceutical research, POS CCE-AXA II, Operation 2.2.1, ID18827, Contract No: 659/2014, amount 37000000 RON, run time 2014-2015

I. NATIONAL RESEARCH GRANTS WON BY COMPETITION

II. INTERNATIONAL RESEARCH GRANTS**International Research Grants – Project Manager**

II.1 Experimental model of peripheral mononuclear cells serum biomarkers for Cladribine treatment response in patients with relapsing-remitting multiple sclerosis: a step towards personalised treatment. Regional Grant for Central and Eastern European Countries 2017 Research Project, Project No: 6943/12.07.2018, amount 100.000 EUR, duration: 2018-2020.

II.2 Assessment of IL-17A, IL-10 and TGF- β serum titres in RRMS patients treated with Avonex, possible biomarkers for treatment response and the impact on them of treatment with Avonex, Project No: 1442 / 2014, Amount: 23900 RON, duration: 2014-2015.

III. POST-DOCTORAL RESEARCHER

III. Postdoctoral research in the program: Supporting research by training specialists within post-doctoral studies programmes, with the following research theme: Heterogeneous responses of immunomodulatory therapies in patients with MS. Contract No: POSDRU/89/1.5/S/64109.

IV. NATIONAL GRANTS APPLIED FOR, ELIGIBLE, UNFUNDED

IV.1 Implementing new, modern interventional methods in the treatment of acute ischaemic stroke: from intraarterial thrombolysis to neurorehabilitation. UEFISCSU, Partner programme, competition 2013, PN-II-PT-PCCA-2013-4-0764. Institution: UMF Targu Mures, amount 400000 EURO, points: 70.

IV.2 The role of biomarkers in inflammatory processes/degenerative processes in MS: Implications upon the heterogenous MS response and the response to immunomodulatory therapies. Internal competition for collective clinical studies, 2013, UMF POS-TGM-CC-13-01-V-01, amount 90000 RON, points: 84.5

B. COORDINATED BACHELORS DEGREES**B.1. BACHELOR'S DEGREES**

During my career I have coordinated more than 50 studies for UMFST both Romanian and English students

PHD**B.2. PHD****1.Coordinator**

I am currently coordinating 10 PhD studies.

2. Awarded PhD

Bărcuțean Laura Iulia – IMMUNE RESPONSE HETEROGENEITY AND CLINICAL EVOLUTION OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH INTERFERON BETA OVER A DECADE (“Cum Laude”, October 2019).

C. MEMBER IN UMF COMMITTEES FOR DIDACTIC EMPLOYMENT

I have coordinated several committees for academic employment in UMFst Targu Mures.

D. NATIONAL AND INTERNATIONAL POST-UNIVERSITARY COURSES - ORGANISATION

1. EFNS Regional Teaching Course, 27-29 sep, 2007, Sovata;
2. Postuniversity lecture: Disorders in deglutition: aetiology, diagnostic, treatment, 11-12 aug 2014, UMF Targu Mures ;
3. Postuniversity lecture: Neuro-immunology, 20-22 nov 2014, UMF Targu Mures;
4. Postuniversity lecture: Neurodegenerative disorders of the peripheral nervous system – clinical and neurophysiological aspects, 25-26 mar 2021, UMFST Targu Mures.

E. NATIONAL AND INTERNATIONAL POSTUNIVERSITARY COURSES - PARTICIPATION

I have participated and graduated from more than 30 national and international postuniversity courses.

F. ACTIVITY IN NATIONAL AND INTERNATIONAL SCIENTIFIC MANIFESTATIONS

I have presented more than 50 lectures at various national and international conferences.

G. SPECIALISATIONS AND ABROAD EXPERIENCES

1. Neurology Service of Centre Hospitalier Universitaire Pierre Wertheimer, Lyon, France (March 2012), Prof. Dr. Christian Confavreux;
2. Tysabri Training and workshop at the Kantonspitaal St. Gallen, Switzerland;
3. Neurology Service of Centre Hospitalier Universitaire Tours, France (15th dec 1997 – 3rd May 1998), Prof. Dr. Alain Autret;
4. Neurophysiology Service of LHopital de la Salpetriere Paris, France (1st July 1997 – 2nd August 1997 1 month), Prof. Dr. Pierre Bouche;
5. Neurology Service of Centre Hospitalier Universitaire Tourse, France (2nd April 1997 – 30 Jun 1997), Prof. Dr. Alain Autret.

H. SCIENTIFIC MANIFESTATIONS

More than 2000 Continuous Medical Education credits.

I. HONOURS AND AWARDS

UEFISCDI: Awards for research articles

1. CODE: PN-II-RU-PRECISI-2015-9-9728: Jung I, Gurzu S, **Bălașa R**, Moțățaiianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. **FI: 4.256.**
2. CODE: PN-III-P1-1.1-PRECISI-2018-26093: Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. **FI: 0.99**
3. CODE: PN-III-P1-1.1-PRECISI-2020-51187: Moțățaiianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. **FI: 2.883**

PHD IN MEDICINE, “CUM LAUDE”;

Health and Research Ministry Order no. 4741/25.08.2003

“IN HONORIS” DISTINCTION – For the support in establishing the Mobile Emergency Service for Resuscitation and Extrication of emergency medical assistance and qualified first-aid integrated system in Romania, celebrating 25 years of SMURD

RECOMMENDATION from Lawrence Steinman, neurology professor, Chair of the Department of Neurology and Neurologica Sciences, US National Academy of Sciences Stanford University, **Hirsch Index 59**

DISTINCTION ON BEHALF OF ROMANIAN SOCIETY OF MULTIPLE SCLEROSIS – for the support given to the multiple sclerosis patients in Romania

Fellowship of INTERNATIONAL FEDERATION OF CLINICAL NEUROPHYSIOLOGY (IFCN) at th IXth International Congress of EMG and Clinical Neurophysiology, 7-11 September, 1999, Prague, Czech Republic for the paper: Visual evoked potentials modifiers in multiple sclerosis patients, abstract published in: *Clin Neurophysiol* 1999; 110: S112. IF 2.979, awarded 1000 USD.

J. MEMBERSHIP IN SCIENTIFIC COMMITTEES OR INTERNATIONAL/NATIONAL SCIENTIFIC SOCIETIES

International

- EFNS Subcommittee multiple sclerosis/demyelinating disease of CNS (2008- 2014);
- EAN Subspecialty Scientific Panel on multiple sclerosis (2014 - present);
- ECTRIMS Council.

National

- Member in directorial committee of Romanian Neurology Society (2012-present)

K. FOUNDING MEMBER

Founding member of the Society for the Study of Diabetic Polyneuropathy, Neurodiab, established in 12 may 2012, Cluj Napoca.

L. ACADEMIC POSITIONS IN UMFST TARGU MURES

1. Senate member UMF Targu Mures (2012 – present);
2. Evaluation Committee and Study Quality Assurance President in the UMF Senate Targu Mures (2012 – present);
3. Member in work committee of UMF Targu Mures for obtaining the authorization for medicine in English language (2013 - present);
4. Member in the Ethic Committee in the UMF Senate, Targu Mures;
5. Director of the doctoral school (2017 - present).
UEFISCDI 2007-2013

M. EXPERT**N. MEMBER IN EDITORIAL AND REDACTIONAL COMMITTEE OF SCIENTIFIC JOURNALS ISI/B+****1. ISI Indexed Journals**

- Romanian Journal of Laboratory Medicine (IF 0.171);
- Acta Endocrinologica (IF: 0.45);
- Archives of Medical Research (IF 2.4);
- Expert Review of Neurotherapeutics (IF: 2.834);

2. B+ Indexed Journals

- Acta Medica Marisiensis;
- Romanian Journal of Neurology;
- The Journal of Critical Care Medicine.

O. REVIEWER

- 2020: Journal of Inflammation Research (IF 4.953)
2020: Journal of Neuroimmunology (IF: 3.125)
2020: Experimental and Therapeutic Medicine (Special Issue) (IF: 1.785)
2020: Health problems of Civilizations

P. MEMBER IN NATIONAL/INTERNATIONAL SCIENTIFIC SOCIETIES**International**

1. European Association of Young Neurologists and Trainees – EAYNT (until 2005);
2. The European Neurological Society - ENS (2003- 2014)
3. European Committee for Treatment and Research in Multiple Sclerosis –ECTRIMS, Council (2009-2012).
4. European Federation of Neurological Societies - EFNS (2003- 2014)
5. European Academy of Neurology - EAN
6. Active corresponding member in American Academy of Neurology - AAN (2007-present)
7. European Stroke Organisation - ESO (2013 - present)
8. Society for the study of Neuroprotection and neuroplasticity (2009 – present)

National

1. Active member in Romanian Society of Neurology (SRN) (1996 - present)
2. Active member in Romanian Society of Stroke (AVC) (1998 - present)
3. Active member in Diabetic Neuropathy Society (Neurodiab) (2010 - present)

Q. REGIONAL COORDINATOR

1. National treatment programme in neurological diseases
2. National programme for acute interventional therapy in ischemic stroke, AP-AVC

R. MEMBER OF NATIONAL AND REGIONAL HEALTH COMMITTEES**National**

1. Member of the national committee for the treatment of MS (2005 - present);
2. Member in the neurology committee of the Health and Family Ministry (2008-2011, 2013-2014, 2019-Present).

Regional

- 1 President of Neurology Committee of County Medical Institution of Mures;
2. President of Speciality Territorial Committee for abroad treatment.

S. INTERNATIONAL MULTICENTRIC STUDIES

Principal investigator in numerous international multicentric studies (over 50), ranging from ischemic stroke treatment, Multiple Sclerosis and Parkinson disease

T. SCIENTIFIC ACTIVITY - PUBLICATIONS

Impact factor for publications: **74.574**
Hirsh – 12

U. FIELDS OF INTEREST FOR SCIENTIFIC RESEARCH

1. Multiple Sclerosis;
2. Cerebrovascular disorders;
3. Parkinson disease;
4. Epilepsy.

V. SCIENTIFIC ACTIVITY

1. First author/co-author for 10 monographies and courses (first author of 5 volumes in the last 5 years)
2. First author/co-author for 9 chapters of monographies (first author of 4 in the last 5 years);
3. First author/co-author/principal investigator of more than 300 papers/scientific posters from which:
 - 47 publications ISI indexed (22 published as first author in ISI indexed journals for the past 5 years)
 - 15 collective publications, ISI indexed
 - 44 scientific papers (first author/co-author) published in extenso in B+ CNCSIS journals

W. PUBLICATIONS (ISI indexed)

- [1] **Balasa R**, Barcutean L, Mosora O, Manu D. Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. *Int J Mol Sci.* 2021;22:8370. FI: 5.923.
- [2] Andone S, Bajko Z, Motataianu A, Mosora O, **Balasa R**. The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review. *Int J Mol Sci.* 2021;22:9032. FI: 5.923.
- [3] Stoian A, Bajko Z, Maier S, Cioflinc RA, Grigorescu BL, Motataianu A, Barcutean L, **Balasa R**, Stoian M. High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). 2021;1182. IF: 1.785.
- [4] Forró T, Bajko Z, Balasa A, **Balasa R**. Dysfunction of the Neurovascular Unit in Ischemic Stroke: Highlights on microRNAs and Exosomes as Potential Biomarkers and Therapy. *Int J Mol Sci.* 2021;22:5261. FI: 4.556. Citări:0. [PubMed]
- [5] Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone Sebastian, Maier S, Draghici IA, Cioban A, **Balasa R**. Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. *J Clin Med.* 2021;30;1382. DOI: 10.3390/jcm10071382. FI: 3.303. Citări:0. [PubMed]
- [6] Bajko Z, Maier S, Motataianu A, Filep RC, Stoian A, Andone S, **Balasa R**. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience. *Acta Neurol Belgica.* 2021; ahead of print. DOI: 10.1007/s13760-021-01651-z. FI: 1.989. Citări:0. [PubMed]
- [7] Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, **Balasa R**. Postpartum cerebral venous thrombosis – a single center experience. *Brain Sciences.* 2021;11:1-9. DOI: 10.3390/brainsci11030327. FI: 3.332. Citări:0. [PubMed]
- [8] Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, Motataianu A, Lata I, **Balasa R**. Clinical immunological correlations in patients with multiple sclerosis treated with natalizumab. *Brain sciences.* 2020;10:1-11. DOI: 10.3390/brainsci10110802. FI: 3.332. Citări 0. [PubMed]
- [9] **Balasa R**, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. *Human Immunology.* 2020;81:273-243. DOI: 10.1016/j.humimm.2020.02.009. FI: 2.412. Citări:11. [PubMed]
- [10] Stoian A, Motataianu A, Barcutean L, Maier S, Bajko Z, Voidazan S, Farcas A, **Balasa R**. Understanding the mechanism of action of intravenous Immunoglobulins: a ten years experience in treating Guillain barré syndrome. *Farmacia.* 2020;68:426-435. DOI: 10.31925/farmacia.2020.3.7. FI: 1.607. Citări:1.
- [11] Romaniuc A, **Bălașa R**, Știrbu N, Maier S, Andone S, Bajko Z, Bărcuțean L, Voidăzan S, Moțățăianu A. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. *Behavioural Neurology.* 2020, Article ID 2594702, DOI: 10.1155/2020/2594702. FI: 1.908. Citări:0. [PubMed]
- [12] Moțățăianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.* 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. FI: 2.883. Citări:3. [PubMed]
- [13] Hutanu A, Iancu M, Maier S, **Balasa R**, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: A single center study. *Ann Ind Acad Neurol.* 2020;23:496-503. Doi:10.4103/aiam.AIAN_74_19. FI: 0.898. Citări:2. [PubMed]
- [14] **Bălașa R**, Maier S, Bărcuțean L, Stoian A, Moțățăianu A. The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: one possible link between neuroinflammation and neurodegeneration. *Revista Română de Medicină de Laborator* 2020, 28 (1), DOI:10.2478/rmlm-2020-0005. FI: 0.800. Citări:1.
- [15] Maier S, Moțățăianu A, Bărcuțean L, Balint A, Huțanu A, Bajko Z, Stoian A, Romaniuc A,

- Andone S, **Bălașa R**. Interferon- β 1a, an immunomodulator in relapsing remitting multiple sclerosis patients. The effect on pro-inflammatory cytokines. *Farmacologia* 2020, 68 (1). DOI:10.31925/farmacologia.2020.1.10, FI: 1.527. Citări:2.
- [16] Karelis G, **Balasa R**, De Bleecker J, Stuchevskaya T, Villa An, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayaguanosa J. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. *Eur Neurol*. 2019;81(5-6):223-230. FI: 1.23. Citări:6. [PubMed]
- [17] Hutanu A, Iancu M, Dobreanu M, Oprea OR, Barbu S, Maier S, Tero-Vescan A, Bajko Z, **Balasa R**. Extended lipid profile in Romanian ischemic stroke patients in relation to stroke severity and outcome:a path analysis model. *Arch Med Sci* 2019; <https://doi.org/10.5114/aoms.2019.89302>. FI: 2.280.
- [18] Bajko Z, Filep RC, Maier S, Motataianu A, Andone S, **Balasa R**. Bilateral vertebral artery without stroke secondary to giant cell arteritis. *Acta Reumatol Port* 2019; 44:155-157. FI: 0.776. Citări:0. [PubMed]
- [19] Maier S, Copotioiu M, Romaniuc A, Andone S, **Bălașa R**. Central-variant reversible encephalopathy syndrome in a young patient with systemic lupus erythematosus. *Acta Neurol Belgica* 2019; 119: 269-271. FI: 1.612. Citări: 0. [PubMed]
- [20] Bărcuțean LI, Romaniuc A, Maier S, Bajkó Z, Moțățăianu A, Huțanu A, Simu I, Andone S, **Bălașa R**. Clinical and serological biomarkers of treatment's response in patients treated continuously with interferon β -1b for more than a decade. *CNS Neurol Disord Drug-Targets* 2018; 17: 720-792. FI: 2.084. Citări:7. [PubMed]
- [21] Bajkó Z, Andone S, Buruian M, Filep R, **Bălașa R**. Unilateral deep cerebral venous sinus thrombosis with reversible secondary parkinsonism. *Acta Neurol Belgica*. Epub 2018. 2020;120:503-506. DOI: 10.1007/s13760-018-0982-0. FI: 1.612. Citări:2. [PubMed]
- [22] Moțățăianu A, Maier S, Bajkó Z, Voidazan S, **Bălașa R**, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. *BMC Neurology* 2018; 18: 126. Doi: 10.1186/s12883-018-1125-1. FI: 2.48. Citări:12. [PubMed]
- [23] **Bălașa R**, Ciurba B, Voidazan S, Simu I, Huțanu A, Andone S, Romaniuc A, Moțățăianu A, Maier S. The matrix metalloproteinases panel in multiple sclerosis patients treated with Natalizumab: A possible answer to Natalizumab non-responders. *CNS Neurol Disord Drug-Targets* 2018; 17: 464-472. FI: 2.084. Citări:3. [PubMed]
- [24] Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. FI: 0.99. Citări:13. [PubMed]
- [25] Huțanu A, Maier M, **Bălașa R**, Oprea OR, Barbu Ș, Voidăzan S, Dobreanu M. Plasma phosphorylated neurofilament heavy chains as a potential marker for ischemic stroke patients. *Rom J Lab Med* 2018; 26: 59-64. DOI: <https://doi.org/10.2478/rmlm-2018-0004>. FI: 0.325. Citări:1.
- [26] **Bălașa R**, Simu M, Voidăzan S, Bărcuțean LI, Bajko Z, Huțanu A, Simu I, Maier S. Natalizumab changes the peripheral profile of the Th17 panel in MS patients: New mechanisms of action. *CNS Neurol Disord Drug-Targets* 2017; 16: ISSN: 1018-1026. FI: 2.188. Citări:15. [PubMed]
- [27] Maier S, **Bălașa R**, Bajkó Z, Simu I, Horvath E. Complete progressive ophthalmoplegia and numb chin syndrome, the first clinical manifestations of a lethal abdominal Burkitt lymphoma. *Neurol Neurochir Polska* 2017; 51: 510-513. FI: 0.857. Citări:1. [PubMed]
- [28] **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățăianu A, Țilea B, Tiu C. Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta 1 serum titers in relapsing remitting multiple sclerosis patients treated with Avonex, possible biomarkers for treatment response. *CNS Neurol Disord Drug- Targets* 2017; 16: 93-101. FI: 2.188. Citări:10. [PubMed]
- [29] Țilea B, Voidăzan S, **Bălașa R**, Huțanu A, Fodor A. CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of central nervous system. *Rom J Lab Med* 2017; 25: DOI:10.1515/rmlm-2016-0043. FI: 0.325. Citări:1.
- [30] Mărginean A, Bălănescu C, Moldovan V, Scridon A, Mărginean M, **Bălașa R**, Maier S, Țăruși M, Dobreanu M. The impact of CY2C19 polymorphism, clinical and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry. *Clin Appl Thromb/Hemost* 2017; 23: 255-265. FI: 2.392. Citări:13. [PubMed]
- [31] Maier S, Bajkó Z, Moțățăianu A, Rusu S, **Bălașa R**. Giant internal carotid artery aneurysm causing Collet-Sicard syndrome. *Acta Neurol Belgica* 2017; 117: 295-297. FI: 0.894. Citări:2. [PubMed]
- [32] Bălașa A, **Bălașa R**, Egyed-Zsigmond I, Chinezu R. Bilateral thalamic glioma: case report and review of the literature. *Turk Neurosurg* 2016; 26: 321-324. FI: 0.576. Citări:5. [PubMed]
- [33] **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățăianu A. An intricate mechanism of action of Avonex in relapsing remitting multiple sclerosis patients: variation of serum titre of interleukin-

- 17A, interleukin-10 and transforming growth factor-beta. *CNS Neurol Disord Drug Targets* 2015; 14: 804-810. FI: 2.702. Citări:7. [PubMed]
- [34] **Bălașa R**, Maier S, Bajkó Z, Pașcanu I, Moțățăianu A. Skeletal muscle Na⁺/K⁺-ATPase pump dysfunction in thyrotoxic periodic paralysis: case report. *Acta Endocrinol (Buc)* 2015; 11: 240-245. FI: 0.210. Citări:2.
- [35] **Bălașa R**, Maier S, Bajkó Z, Moțățăianu A, Crișan A, Bălașa A. Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. *Acta Neurol Belgica* 2015; 115: 635-642. FI: 0.598. Citări:4. [PubMed]
- [36] Maier S, Buruian M, Maier A, Moțățăianu A, Voidăzan S, Bajkó Z, **Bălașa R**. The determinants of depression in a Romanian cohort of multiple sclerosis patients. *Acta Neurol Belgica* 2015; DOI: 10.1007/s13760-015-0547-4. FI: 0.598. Citări:4 [PubMed]
- [37] Bajkó Z, **Bălașa R**, Szatmári S, Rusu S, Moțățăianu A, Maier S. The role of ultrasound in the diagnosis of temporal arteritis. *Neurol Neurochir Polska* 2015; 49: 139-143. FI: 0.641. Citări:2. [PubMed]
- [38] Stoian A, Bănescu C, **Bălașa R**, Moțățăianu A, Stoian M, Moldovan VG, Voidăzan S, Dobreanu M. Influence of GSTM1, and GSTP1 polymorphisms on type 2 diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk. *Dis Markers* 2015; ID 638693. FI: 1.562. Citări:23. [PubMed]
- [39] Jung I, Gurzu S, **Bălașa R**, Moțățăianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. FI: 4.256. Citări:12.[PubMed]
- [40] **Bălașa R**, Maier S, Gliga Baubec E, Bajkó Z, Bălașa A. Cerebellar and brainstem variant of posterior reversible encephalopathy syndrome. *Acta Neurol Belg* 2015; 115: 401-403. FI: 0.598. Citări:1.[PubMed]
- [41] **Bălașa R**, Bajkó Z, Moțățăianu A, Maier A, Maier S. Neuromyelitis optica associated with painful dystonia: case report and literature review. *Acta Neurol Belg* 2015; 115: 169-171. FI: 0.598. Citări:1. [PubMed]
- [42] **Bălașa R**, Maier S, Moțățăianu A, Bajkó Z, Moldovan O, Benedek E. A case of fatal acute intermittent porphyria: laboratory diagnosis and pathogenesis considerations. *Rev Rom Med Lab* 2014; 22: 325-333. FI: 0.171. Citări:1.
- [43] Treabă AC, **Bălașa R**, Podoleanu DM, Simu IP, Buruian MM. Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? *Diagn Interv Radiol* 2014; 20: 178-184. FI: 1.427. Citări:9. [PubMed]
- [44] Moțățăianu A, **Bălașa R**, Voidăzan S, Bajkó Z. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. *BioMed Res Internat* 2013, Article ID 507216. FI: 2.706. Citări:11. [PubMed]
- [45] **Bălașa R**, Bajkó Z, Huțanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. *Mult Scler J* 2013; 19: 885-890. FI: 4.863. Citări:27. [PubMed]
- [46] **Bălașa R**, Huțanu A, Bajkó Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-beta treatment in multiple sclerosis? *Rom J Lab Med* 2011; 19: 381-389. FI: 0.091. Citări:10.
- [47] **Bălașa R**, Huțanu A, Feier C, Bajkó Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients. *Rom J Lab Med* 2010; 18: 39-50. FI: 0.113. Citări:2.